Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Diabetic Retinopathy

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The impact of swithching faricimab in the treatment of neovascular age-related macular degeneration: a real-world analysis.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2025

Same author

Herpes simplex uveitis as a cause of persistent high intraocular pressure after cataract surgery.

Clinical & experimental ophthalmology·2016

Same author

Uveal Effusion: Clinical Features, Management, and Visual Outcomes in a Retrospective Case Series.

Journal of glaucoma·2015

Same author

One-step reconstruction of large lower eyelid defects: technique and outcomes.

Clinical & experimental ophthalmology·2014

Same author

Nanosecond-laser application in intermediate AMD: 12-month results of fundus appearance and macular function.

Clinical & experimental ophthalmology·2013

Same author

Contrast-induced transient cortical blindness.

Clinical & experimental optometry·2012

Search research articles

Related Experiment Videos

Erectile dysfunction following intravitreal bevacizumab.

Jayshan Yohendran¹, Devinder Chauhan

¹Vision Retinal Institute, 852 Whitehorse Road, Box Hill VIC 3128, Australia.

Middle East African Journal of Ophthalmology

|September 17, 2010

Summary

Intravitreal bevacizumab injections for eye conditions may cause temporary erectile dysfunction. This potential side effect, possibly organic, warrants further investigation in patients receiving this treatment.

Keywords:

Antivascular Endothelial Growth Factor Agents Bevacizumab Erectile Dysfunction

Related Experiment Videos

Area of Science:

Ophthalmology
Urology
Pharmacology

Background:

Intravitreal anti-VEGF agents are increasingly used for ocular diseases.
Systemic complications from intravitreal injections are a concern.
Erectile dysfunction is not a commonly reported side effect of intravitreal bevacizumab.

Purpose of the Study:

To report a case of erectile dysfunction following intravitreal bevacizumab administration.
To postulate an organic mechanism for this side effect.
To raise awareness of erectile dysfunction as a potential adverse event.

Main Methods:

A case study of a 40-year-old male with macular edema.
Administration of intravitreal bevacizumab therapy.
Clinical observation and documentation of side effects, including erectile dysfunction.

Main Results:

The patient developed transient erectile dysfunction after each of two bevacizumab injections.
The patient had mild hypertension as his only comorbidity.
No prior literature reported erectile dysfunction with intravitreal bevacizumab.

Conclusions:

Erectile dysfunction may be an underrecognized side effect of intravitreal bevacizumab.
The etiology could be organic, potentially due to systemic absorption.
Further research is needed to confirm this association and explore mechanisms.